On track to integrate major part of Viatris'' acquired biosimilars biz this fiscal: Kiran Mazumdar-Shaw
Biocon Biologics is on track to integrate a major part of the acquired biosimilars business of long-term partner Viatris in the current fiscal, the company's Executive Chairperson Kiran Mazumdar-Shaw has said. Biocon Biologics, a unit of the Bengaluru-based biotechnology major, had announced earlier this year that it has completed the integration of the acquired biosimilars business from Viatris in over 70 countries in emerging markets effective July 1, 2023.
Now, it is looking to integrate the acquired biosimilars business in the remaining markets like North America and Europe.
«We are on track to integrate a major part of the acquired business in a phased manner during FY24,» Mazumdar-Shaw said in her address to the company's shareholders in the Annual Report for 2022-23, which was released on Wednesday.
Direct commercial presence in many global markets will allow Biocon Biologics to devise more sustainable and targeted strategies to make biosimilars accessible to the maximum number of patients and healthcare providers, she added.
